Sinopharm Group
Logotype for Sinopharm Group Co Ltd

Sinopharm Group (1099) investor relations material

Sinopharm Group Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Sinopharm Group Co Ltd
Q3 2026 earnings summary26 Oct, 2026

Executive summary

  • 9M 2026 revenue was RMB427.61bn and net profit RMB8.08bn; revenue and net profit were below 9M 2025 levels.

  • Net profit attributable to equity holders of the parent was RMB5.31bn, compared with RMB5.31bn in 9M 2025.

Financial highlights

  • Operating profit was RMB10.78bn vs RMB10.87bn; total profit was RMB10.80bn vs RMB10.88bn in 9M 2025.

  • Operating revenue was RMB427.61bn vs RMB431.48bn; operating cost was RMB397.73bn vs RMB400.21bn.

  • Net profit was RMB8.08bn vs RMB8.10bn; parent-attributable net profit was RMB5.31bn vs RMB5.31bn.

  • Operating cash outflow was RMB23.93bn, improving from RMB39.08bn in 9M 2025.

Key financial ratios and metrics

  • Basic and diluted EPS were both RMB1.70 for 9M 2026 and 9M 2025.

  • Total assets were RMB407.87bn at 30 Sep 2026 vs RMB390.21bn at 31 Dec 2025; total liabilities were RMB268.60bn vs RMB255.86bn.

  • Consolidated equity was RMB139.27bn at 30 Sep 2026 vs RMB134.35bn at 31 Dec 2025.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Sinopharm Group earnings date

Logotype for Sinopharm Group Co Ltd
Q4 202625 Mar, 2027
Sinopharm Group
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Sinopharm Group earnings date

Logotype for Sinopharm Group Co Ltd
Q4 202625 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Sinopharm Group Co. Ltd. is a healthcare company specializing in the distribution and supply of pharmaceutical products, medical devices, and healthcare services. The company operates an extensive distribution network, providing a wide range of medicines, vaccines, and diagnostic products to hospitals, pharmacies, and other healthcare institutions. Sinopharm is also involved in retail pharmacy operations and healthcare logistics services, supporting the medical and pharmaceutical sectors. The company is headquartered in Shanghai, China, and its shares are listed on the SEHK.